Devgen NV Drug Candidates May Promise Breakthrough In The Treatment Of Rheumatoid Arthritis And Other Inflammatory Diseases

August 24, 2006 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

Devgen (Euronext Brussels: DEVG) announced today that, following encouraging results from studies in animals, one of its preclinical programs may show promise for the treatment of inflammatory diseases.

Twitter
LinkedIn
Facebook
Email
Print

Preclinical Europe